Nautilus Biotechnology (NAUT) CMO receives grant of 160,000 stock options

Rhea-AI Filing Summary

Nautilus Biotechnology Chief Marketing Officer awarded stock options

Nautilus Biotechnology granted Chief Marketing Officer Kentaro Suzuki a stock option to acquire 160,000 shares on March 2, 2026. The option has a $0.00 exercise price and vests over time, starting from a vesting commencement date of January 1, 2026.

One quarter of the option vests on the one-year anniversary of the vesting commencement date, with the remaining shares vesting monthly in equal installments, subject to his continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Suzuki Kentaro

Role Chief Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	160,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 160,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Suzuki Kentaro

(Last) (First) (Middle)

C/O NAUTILUS BIOTECHNOLOGY, INC.

2701 EASTLAKE AVE EAST

(Street)

SEATTLE WA 98102

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.32	03/02/2026		A		160,000		(1)	03/02/2036	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Remarks:

	/s/ Matthew Murphy, as Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nautilus Biotechnology (NAUT) report for Kentaro Suzuki?

Nautilus Biotechnology reported a stock option grant to Chief Marketing Officer Kentaro Suzuki for 160,000 shares. The award was recorded on March 2, 2026, as a derivative acquisition under code A, reflecting a compensatory grant rather than an open-market purchase or sale.

How many shares are covered by Kentaro Suzuki’s stock option at Nautilus Biotechnology (NAUT)?

The stock option granted to Kentaro Suzuki covers 160,000 shares of Nautilus Biotechnology common stock. This entire amount is reflected as directly owned following the transaction, with the award structured as an option rather than currently issued shares of stock.

What is the vesting schedule for Kentaro Suzuki’s Nautilus Biotechnology (NAUT) stock option?

The option vests over time, starting from a January 1, 2026 vesting commencement date. Twenty-five percent vests on the one-year anniversary, and the remaining shares vest in equal monthly installments over 36 months, contingent on continued service as a “Service Provider.”

What is the exercise price of Kentaro Suzuki’s stock option at Nautilus Biotechnology (NAUT)?

The reported transaction lists an exercise price of $0.00 per share for the stock option. This reflects how the award is recorded in the filing; it is characterized as a compensatory option grant rather than an open-market transaction at a prevailing market price.

Is Kentaro Suzuki’s Nautilus Biotechnology (NAUT) option grant a buy or a sale?

The transaction is classified as an acquisition through a grant, not a market buy or sale. It is coded as “A” for grant or award, meaning Suzuki received the option as part of compensation instead of purchasing or selling shares in the open market.

What conditions affect vesting of Kentaro Suzuki’s Nautilus Biotechnology (NAUT) stock option?

Vesting is conditioned on Suzuki maintaining continuous status as a “Service Provider” under the company’s 2021 Equity Incentive Plan. If this status continues through each vesting date, the option will vest according to the specified one-year cliff and subsequent monthly vesting schedule.